Mpox, Monkeypox clinical trials
The registry lists 42 studies for Mpox, Monkeypox across more than 10 countries. 17 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-15.
Status
- Completed
- 13
- Active, not recruiting
- 9
- Recruiting
- 8
- Not yet recruiting
- 4
- Enrolling by invitation
- 4
- Terminated
- 2
Phase
- Phase 2
- 10
- Phase 3
- 7
- Phase 1
- 4
- Phase 4
- 3
Where
- Democratic Republic of the Congo
- 18
- United States
- 8
- Uganda
- 3
- United Kingdom
- 3
- China
- 3
- Spain
- 3
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Institute of Tropical Medicine, Belgium (5) · Shanghai Institute Of Biological Products (2) · Bavarian Nordic (2) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (2) · Centers for Disease Control and Prevention (2) · ANRS, Emerging Infectious Diseases (2) · BioNTech SE (2)
Studies
Recruiting first, then most recently updated. Showing 42 of 42 — search for more.
- Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)RecruitingNCT070934891 country
- New York City Observational Study of Mpox ImmunityEnrolling by invitationNCT056548831 country
- Smart Analysis and Decision-Making for Emerging Infectious DiseasesEnrolling by invitationNCT07678619Not applicable1 country
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in AfricaRecruitingNCT07379580Phase 22 countries
- Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort StudyRecruitingNCT055623231 country
- Tecovirimat (ST-246) Treatment for Orthopox Virus ExposureAvailableNCT02080767
- Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRCRecruitingNCT076340811 country
- Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC CohortNot yet recruitingNCT07592429Not applicable
- Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : GuineaNot yet recruitingNCT075342671 country
- Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at RiskRecruitingNCT058799651 country
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.RecruitingNCT07377175Phase 11 country
- Prospective Follow-up After MVA-BN Booster VaccinationNot yet recruitingNCT073428291 country
- Neutralizing Power of Serum Antibodies - 2RecruitingNCT07085611Not applicable1 country
- Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the CongoNot yet recruitingNCT07253675Phase 2
- A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live VaccineRecruitingNCT06771479Phase 11 country
- Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)Enrolling by invitationNCT070677231 country
- Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)Enrolling by invitationNCT070558671 country
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox VaccinesCompletedNCT05988203Phase 1/22 countries
- Performance Evaluation of Mpox Molecular POC DiagnosticsCompletedNCT076206001 country
- Mpox Paediatric and Adolescent Clinical StudyCompletedNCT059477866 countries
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCTActive, not recruitingNCT05745987Phase 43 countries
- Study of Tecovirimat for Human Mpox VirusTerminatedNCT05534984Phase 36 countries
- Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the CongoActive, not recruitingNCT07499739Phase 41 country
- Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus DiseaseActive, not recruitingNCT05597735Phase 33 countries
- An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRCActive, not recruitingNCT06839989Phase 21 country
- Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIVTerminatedNCT060459231 country
- Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in ContactsCompletedNCT072673901 country
- Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRCActive, not recruitingNCT06844487Phase 31 country
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the CongoCompletedNCT02977715Phase 31 country
- Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox VaccineCompletedNCT05512949Phase 21 country
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsActive, not recruitingNCT07199569Phase 21 country
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for MpoxCompletedNCT05740982Phase 22 countries
- Ocular Complications of Mpox in the Democratic Republic CongoCompletedNCT065798851 country
- Tecovirimat in Non-hospitalized Patients With MonkeypoxSuspendedNCT05534165Phase 31 country
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRCCompletedNCT05734508Phase 41 country
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRCActive, not recruitingNCT06844500Phase 31 country
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus InfectionsActive, not recruitingNCT06549530Phase 22 countries
- Tecovirimat for Treatment of Monkeypox VirusCompletedNCT05559099Phase 21 country
- Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in ColombiaActive, not recruitingNCT06223919Phase 31 country
- Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care OnlyCompletedNCT067215851 country
- Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIVCompletedNCT059654274 countries
- A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of AgeCompletedNCT05995275Phase 1/21 country